A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients with Advanced Mesothelin-Expressing Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
TCR2 Therapeutics Inc.
Start Date
April 11, 2023
End Date
November 18, 2024
Administered By
Duke Cancer Institute
Awarded By
TCR2 Therapeutics Inc.
Start Date
April 11, 2023
End Date
November 18, 2024